Kronox Lab Sciences Board Overhaul: New MD, CFO Appointed; Promoters Exit
Kronox Lab Sciences has completed a share transfer, with Indo Borax & Chemicals Limited acquiring 64.26% stake. The company appointed Suresh Kalra as MD & CEO, Sunil Malhotra and Harsh Malhotra as executive directors, and Amit Sharma, Anuradha Maheshwari, and Dhananjay Tapasvi as independent directors. Shashikant Bharuka is the new CFO. Several board members and the CFO resigned.
The change in majority shareholding and the appointment of a new Managing Director, CEO, CFO, and several directors represent a significant shift in the company's leadership and control, which is expected to have a high impact on its future strategy and operations.
The announcement details significant board changes, including new appointments and resignations, as well as a change in shareholding. While these are material events, they represent a restructuring and do not inherently indicate positive or negative performance for the company at this stage.
Kronox Lab Sciences Limited has announced significant changes following a board meeting held on September 29, 2026. The company confirmed the completion of a share transfer agreement where the Sellers (Mr. Ketan Vinodchandra Ramani, Mr. Pritesh Vinodchandra Ramani, and Mr. Jogindersingh Gianchand Jaswal) transferred an aggregate of 2,38,44,000 equity shares, representing 64.26% of the company's paid-up equity share capital, to Indo Borax & Chemicals Limited (Purchaser).
Consequent to this transaction, the Sellers collectively hold 9.95% of the voting share capital, and they, along with other members of the promoter group, have ceased to be part of the promoter group. The Board of Directors also approved several key appointments and noted resignations.
Mr. Suresh Kalra has been appointed as an additional Director, Managing Director, and Chief Executive Officer for a term of 5 years. Mr. Sunil Malhotra and Mr. Harsh Malhotra have been appointed as additional directors (executive and non-independent), with Mr. Sunil Malhotra also serving as Whole-time Director, each for a 5-year term.
Additionally, Mr. Amit Kumar Sharma, Ms. Anuradha Suneet Maheshwari, and Mr. Dhananjay Tapasvi have been appointed as additional non-executive independent directors for 5-year terms. Mr. Shashikant Bharuka has been appointed as the Chief Financial Officer and Key Managerial Personnel for a 5-year term.
Several resignations were also recorded: Mr. Jogindersingh Gianchand Jaswal resigned as Managing Director, Mr. Ketan Ramani and Mr. Pritesh Vinodchandra Ramani resigned as executive directors, and Mr. Samir Gadhiya resigned as Chief Financial Officer. Furthermore, Mr. Parth Shah, Ms. Krutika Arunkumar Negandhi, and Mr. Satish Kumar resigned as non-executive independent directors.
Following these changes, the Board has reconstituted its committees, including the Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee, and Corporate Social Responsibility Committee, with new members and chairpersons.
In a related development, consultancy agreements are to be executed with Mr. Jogindersingh Gianchand Jaswal, Mr. Ketan Ramani, and Mr. Pritesh Vinodchandra Ramani.
What to do with a filing like this
Kronox Lab Sciences Limited filed this with the NSE as a statutory disclosure, categorised under corporate governance report. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Kronox Lab Sciences Limited. Read the original for the full detail.